XML 52 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2021
Shareholders' Equity (Tables) [Line Items]  
Schedule of issued and outstanding
    December 31, 2021   December 31, 2020 
    Authorized   Issued and Outstanding   Authorized   Issued and Outstanding 
Ordinary shares    100,000,000    51,791,441    100,000,000    46,100,173 
Total    100,000,000    51,791,441    100,000,000    46,100,173 

 

Schedule of share-based awards to employees, officers and directors
   Year ended
December 31,
   Year ended
December 31,
 
   2021   2020 
   Number of   Weighted   Number of   Weighted 
   share-based   average   share-based   average 
   payment   exercise   payment   exercise 
   awards   price   awards   price 
Outstanding at beginning of year   3,372,626   $5.27    3,410,406   $1.89 
Changes during the year:                    
Granted   180,319    40.12    1,327,957   $13.70 
Exercised   (1,043,142)   7.66    
*(1,267,012
)  $8.94 
Forfeited   (118,954)   10.18    
-
    
-
 
Expired   (66,606)   16.37    
-
    
-
 
Cancelled   
-
    
-
    (98,725)   1.92 
Outstanding at end of year   2,324,243    6.17    3,372,626   $5.27 
Exercisable at end of year   1,618,777    3.35    2,191,042   $5.67 

 

Schedule of Black-Scholes option-pricing model
    Year ended
December 31,
2021
    Year ended
December 31,
2020
 
Dividend yield   0     0  
Expected volatility   50.27% - 52.71%     57.34%-44.40%  
Risk-free interest rate   0.66% - 1.61%     0.27%-1.61%  
Contractual term (years)   0–10     5–10  

 

   2021   2020 
Dividend yield   0    0 
Expected volatility   50.27%-51.84%    45.11%-55.97% 
Risk-free interest rate   0.66%-1.61%    0.23%-1.61% 
Contractual term (years)   10    10 

 

Schedule of information concerning outstanding and exercisable awards
December 31, 2021  
Awards outstanding     Awards exercisable  
      Number of     Weighted     Number of     Weighted  
      awards     average     award     average  
      outstanding     remaining     exercisable     remaining  
Exercise     at end of     contractual     at end of     contractual  
price     year     life (years)     year     life (years)  
$ 1.92       192,927       0.04       192,927       0.04  
$ 2.21       1,769,513       7.89       1,288,236       7.89  
$ 16.00      

161,484

      5.43      

114,477

      4.22  
$ 23.19       21,000       9.78      
-
     
-
 
$ 23.84       30,000       9.88      
-
     
-
 
$ 30.93       20,000       8.81       20,000       8.81  
$ 30.66       12,000       9.53      
-
     
-
 
$ 40.21       17,319       9.19       3,137       9.19  
$ 49.68       100,000       9.05      
-
     
-
 

December 31, 2020 
Awards outstanding   Awards exercisable 
    Number of   Weighted   Number of   Weighted 
    awards   average   award   average 
    outstanding   remaining   exercisable   remaining 
Exercise   at end of   contractual   at end of   contractual 
price   year   life (years)   year   life (years) 
$0.01    186,815    0.33    186,815    0.33 
$1.92    269,714    1.18    269,714    1.18 
$2.21    2,191,349    6.22    1,188,914    6.22 
$16.00    444,748    8.89    283,933    8.89 
$18.00    260,000    3.86    260,000    3.86 
$30.93    20,000    9.81    1,666    9.81 

 

December 31, 2021  
Awards outstanding     Awards exercisable  
      Number of     Weighted     Number of     Weighted  
      awards     average     awards     average  
      outstanding     remaining     exercisable     remaining  
Exercise     at end of     contractual     at end of     contractual  
price     year     life (years)     year     life (years)  
  $0.00-0.01      
120,757*)
      -       73,679       -  
  $2.21       1,130,143       7.95       716,448       7.95  
  $16.00       88,500       7.48       35,791       6.09  
  $17.63-$64.61       1,421,530       9.68       19,438       8.98  

 

December 31, 2020 
Awards outstanding   Awards exercisable 
    Number of   Weighted   Number of   Weighted 
    awards   average   awards   average 
    outstanding   remaining   exercisable   remaining 
Exercise   at end of   contractual   at end of   contractual 
price   year   life (years)   year   life (years) 
                       
 $2.21    1,995,625    9.05    1,019,695    9.05 
 $16.00    205,000    9.62    37,917    9.62 
 $26.56-$59.20    180,500    9.93    4,167    9.93 

 

Schedule of share-based compensation expenses
   Year Ended December 31, 
   2021   2020   2019 
   (U.S. dollars in thousands) 
Cost of revenue   51    
-
    
-
 
Research and development   3,248    3,384    661 
Sales and Marketing (*)   2,442    9,252    617 
General and administrative   13,065    12,145    14,967 
                
    18,806    24,781    16,245 

 

Employees, Officers and Directors [Member]  
Shareholders' Equity (Tables) [Line Items]  
Schedule of issued and outstanding
   Year ended    Year ended 
   December 31, 2021   December 31, 2020 
   Number of   Weighted   Number of   Weighted 
   share-based   average   share-based   average 
   payment awards   exercise
price
   payment
awards
   exercise
price
 
Outstanding at beginning of year   2,381,125   $4.14    1,667,267   $2.21 
Changes during the year:                    
Granted   1,418,665   $27.57   730,734    13.53 
Issued due to business combination   117,536    0.00    
-
    
-
 
Exercised   (837,724)   3.11    
-
    
-
 
Forfeited   (318,672)   19.69    
-
    
-
 
Expired   
-
    
-
    
-
    
-
 
Cancelled   
-
    
-
    (16,876)   2.21 
Outstanding at end of year   

2,760,930

   $

15.85

    2,381,125    4.14 
Exercisable at end of year   

845,356

   $3.58    1,061,778    2.80